U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C24H32N2O2.2ClH
Molecular Weight 453.445
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EPRAZINONE HYDROCHLORIDE

SMILES

Cl.Cl.CCOC(CN1CCN(CC(C)C(=O)C2=CC=CC=C2)CC1)C3=CC=CC=C3

InChI

InChIKey=BPMQVOKMMQFZGV-UHFFFAOYSA-N
InChI=1S/C24H32N2O2.2ClH/c1-3-28-23(21-10-6-4-7-11-21)19-26-16-14-25(15-17-26)18-20(2)24(27)22-12-8-5-9-13-22;;/h4-13,20,23H,3,14-19H2,1-2H3;2*1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C24H32N2O2
Molecular Weight 380.5231
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=421 | http://en.pharmacodia.com/web/drug/1_11802.html

Eprazinone has been variously described as having mucolytic or expectorant properties as well as a direct relaxant action on bronchial smooth muscle and it suppress the excitation of cough center to stop coughing. It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia The most commonly reported adverse reactions include loss of appetite, nausea/vomiting, stomach discomfort, diarrhea (including loose stool) and symptom of irritation.

CNS Activity

Curator's Comment: Eprazinone suppresses the excitation of cough center to stop coughing.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Eftapan

Approved Use

It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia
Palliative
Eftapan

Approved Use

It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia
Palliative
Eftapan

Approved Use

It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia.
Palliative
Eftapan

Approved Use

It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia.
PubMed

PubMed

TitleDatePubMed
Non-pigmented fixed drug eruption induced by eprazinone hydrochloride.
2005 Dec 1
Effects of automated external lubrication on tablet properties and the stability of eprazinone hydrochloride.
2009 Mar 31
Patents

Sample Use Guides

take 60-90mg of the active ingredient in 3 divided doses a day
Route of Administration: Other
Eprazinone displayed a rather weak inhibition of [125I]BH-SPbinding to NK1R, at a concentration of 25 uM, and an antagonistic effect of about 30%, NK1R blockade could contribute to its mucolytic activity or could even be a hint to a still unrevealed mode of action.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:19:08 GMT 2023
Edited
by admin
on Fri Dec 15 15:19:08 GMT 2023
Record UNII
394X1L8I9Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EPRAZINONE HYDROCHLORIDE
JAN   MART.   WHO-DD  
Common Name English
NSC-317935
Code English
EPRAZINONE HCL
Common Name English
EPRAZINONE HYDROCHLORIDE [JAN]
Common Name English
EPRAZINONE HYDROCHLORIDE [MART.]
Common Name English
Eprazinone hydrochloride [WHO-DD]
Common Name English
3-(4-(.BETA.-ETHOXYPHENETHYL)PIPERAZIN-1-YL)-2-METHYLPROPIOPHENONE DIHYDROCHLORIDE
Systematic Name English
EPRAZINONE DIHYDROCHLORIDE [MI]
Common Name English
Code System Code Type Description
PUBCHEM
73356
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
MERCK INDEX
m4958
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID1046631
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
SMS_ID
100000092366
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
CHEBI
31551
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
EVMPD
SUB01919MIG
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
FDA UNII
394X1L8I9Y
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
RXCUI
236310
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY RxNorm
MESH
C007608
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
ECHA (EC/EINECS)
233-872-8
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
NSC
317935
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
CAS
10402-53-6
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
DRUG BANK
DBSALT001085
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
ChEMBL
CHEMBL1885437
Created by admin on Fri Dec 15 15:19:08 GMT 2023 , Edited by admin on Fri Dec 15 15:19:08 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY